passages: 2711
passages: document
passages: Plasma AGE-peptides and C-peptide in early-stage diabetic nephropathy patients on thiamine and pyridoxine therapy . AIM The aim of the study was to evaluate circulatory AGE-peptide levels in diabetic nephropathy and to observe the effects of thiamine ( vitamin B1 ) and pyridoxine ( vitamin B6 ) therapy . METHODS Type 2 diabetic patients ( N.=57 ) were divided into two groups as " with nephropathy " ( N.=27 ) and " without nephropathy " ( N.=30 ) . Diabetic nephropathy patients were treated with either B6 ( N.=12 ) ( 250 mg/day ) or B1+B6 ( N.=15 ) ( 250 mg/day , each ) for five months . At the beginning and the end of the experimentation period , glucose , HbA1c , triglyceride , cholesterol , insulin , C-peptide , thiamine pyrophosphate , pyridoxal phosphate and AGE- peptides were measured . RESULTS AGE-peptides were higher in the diabetic group with nephropathy than without nephropathy ( P=0.005 ) . Within five months AGE-peptides increased in the diabetic group without nephropathy ( P=0.042 ) but not in the group with nephropathy treated either with B1+B6 or B6 . In B6 treated group a substantial decrease was observed in HbA1c ( P=0.033 ) . B1+B6 or B6 treatment both caused an increase in C-peptide ( P=0.006 , P=0.004 ) . CONCLUSION Among the parameters measured , plasma AGE-peptides was the only parameter found to be higher in type 2 diabetes mellitus patients " with nephropathy " than " without nephropathy " . However , patients with nephropathy treated with B1+B6 or B6 did not display any further increase in AGE-peptides within five months . Both of the treatments caused an increase in C-peptide .
entities: 2712
entities: Intervention_Pharmacological
entities: thiamine ( vitamin B1 )
entities: 2713
entities: Intervention_Pharmacological
entities: pyridoxine ( vitamin B6 )
entities: 2714
entities: Intervention_Pharmacological
entities: B6
entities: 2715
entities: Intervention_Pharmacological
entities: B1+B6
entities: 2716
entities: Intervention_Pharmacological
entities: B1+B6
entities: 2717
entities: Intervention_Pharmacological
entities: B6 .
entities: 2718
entities: Intervention_Pharmacological
entities: B6
entities: 2719
entities: Intervention_Pharmacological
entities: B1+B6
entities: 2720
entities: Intervention_Pharmacological
entities: B6
entities: 2721
entities: Intervention_Pharmacological
entities: B1+B6
entities: 2722
entities: Intervention_Pharmacological
entities: B6
entities: 2723
entities: Outcome_Physical
entities: Plasma AGE-peptides and C-peptide
entities: 2724
entities: Outcome_Physical
entities: circulatory AGE-peptide levels
entities: 2725
entities: Outcome_Physical
entities: glucose , HbA1c , triglyceride , cholesterol , insulin , C-peptide , thiamine pyrophosphate , pyridoxal phosphate and AGE- peptides
entities: 2726
entities: Outcome_Physical
entities: AGE-peptides
entities: 2727
entities: Outcome_Physical
entities: AGE-peptides
entities: 2728
entities: Outcome_Physical
entities: HbA1c
entities: 2729
entities: Outcome_Physical
entities: C-peptide
entities: 2730
entities: Outcome_Physical
entities: plasma AGE-peptides
entities: 2731
entities: Outcome_Physical
entities: AGE-peptides
entities: 2732
entities: Outcome_Physical
entities: C-peptide .
entities: 2733
entities: Participant_Condition
entities: early-stage diabetic nephropathy patients
entities: 2734
entities: Participant_Condition
entities: Type 2 diabetic patients
entities: 2735
entities: Participant_Sample-size
entities: N.=57
entities: 2736
entities: Participant_Condition
entities: Diabetic nephropathy patients
entities: 2737
entities: Participant_Condition
entities: type 2 diabetes mellitus patients
entities: 2738
entities: Participant_Condition
entities: patients